Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford and benefits from excellent links with the global Ludwig and local Oxford research communities.
Reverse genetics – the approach of understanding gene function by analysing the effects of altered DNA sequences – has been used on a large scale to ‘label’ genes with particular functions in model organisms, but it is technically difficult in human cells. Sebastian Nijman and colleagues now present a scalable approach to link genotype to phenotype in human cells, which could be used to study poorly characterised human genes.
Do you want to know more about Open Access? Find out about Act on Acceptance & ORCID from an expert? Book a place for our session on Tuesday 23rd August, 2-3pm in Room B at the WTCHG. Juliet Ralph, the Open Access Subject librarian, will be available for your toughest questions.
Parallel reverse genetic screening in mutant human cells using transcriptomics. Mol Syst Biol, 12 (8).
ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome. Cell Death Differ. Article
Introducing STRaNDs: shuttling transcriptional regulators that are non-DNA binding. Nat Rev Mol Cell Biol, 17 (8). Article
5-hydroxymethylcytosine marks regions with reduced mutation frequency in human DNA. Elife, 5 (MAY2016). Article
Simultaneous single-molecule epigenetic imaging of DNA methylation and hydroxymethylation. Proc Natl Acad Sci U S A, 113 (16). Article
Our researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Many of the research groups are interested the causes and consequences of differences among cells within a tumour and variability among different tumours. Find out more about the Ludwig research groups.
Ludwig Seminars take place in the NDMRB (TDI) Basement Seminar Room. All University members welcome.
Dr Daniel Anderson: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer, 07/Sep/2016 11:00
Browse the Ludwig Seminar Series